



June 28, 2024

Pharma Foods International Co. Ltd.

**A milestone has been achieved as set forth in an Exclusive Licensing Agreement between PFI and Mitsubishi Tanabe Pharma Corporation for a New Investigational Therapeutic Antibody for autoimmune diseases**

Pharma Foods International Co. Ltd. (Head Office: Kyoto; President & Representative Director, CEO: Mujo Kim, hereinafter referred as to “PFI” ) announced that a milestone has been achieved as set forth in an Exclusive Licensing Agreement (hereinafter referred as to “the License Agreement” ) for a new investigational therapeutic antibody for autoimmune diseases which PFI entered into with Mitsubishi Tanabe Pharma Corporation (Head office: Osaka, Representative Director, CEO: Akihiro Tsujimura, hereinafter referred as to “MTPC” ).

This investigational therapeutic antibody has been improved and created through collaborative research between PFI and MTPC, based on the antibody jointly developed with Mamoru SATO, Ph. D, professor emeritus, Yokohama City University and Satoshi KANAZAWA, Ph. D, Assistant Professor, Nagoya City University, by utilizing its propriety antibody production technology “ALAgene® technology”※1.

PFI and MTPC entered into the License Agreement in January 2021 for this investigational therapeutic antibody.

An initial Clinical Trial Notification was submitted to Pharmaceutical and Medical Devices Agency (PMDA), and the 30-day review has been completed. Phase I clinical trials for this investigational therapeutic antibody will begin in the future. Therefore, PFI will receive a milestone payment as set forth in the License Agreement.

Accede to a mission “Make a social contribution thorough conducting research of pharmaceuticals and foods” , PFI is going to make more every effort to research and develop drugs on the most prioritized disease area of unmet medical needs (Unmet medical needs are a condition or symptom whose treatment or diagnosis is not addressed adequately by available therapy).

<Reference>

\*1 About ALAgene® technology

ALAgene® technology was developed by PFI based on the chicken monoclonal antibody production unique technology. In conventional methods using mammals, it is difficult to produce antibodies against antigens with high homology. ALAgene® technology is a platform technology which is able to develop and make an antibody with high affinity from the chickens.